Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Diluted Average) (2019 - 2025)

ImmunityBio (IBRX) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $919.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 31.33% to $919.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $919.9 million through Dec 2025, up 31.33% year-over-year, with the annual reading at $919.9 million for FY2025, 31.33% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $919.9 million at ImmunityBio, down from $946.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $946.6 million in Q3 2025, with the low at $382.7 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $568.1 million, with a median of $465.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 1.74% in 2022, then skyrocketed 57.06% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $389.2 million in 2021, then grew by 2.74% to $399.9 million in 2022, then increased by 27.19% to $508.6 million in 2023, then skyrocketed by 37.71% to $700.4 million in 2024, then soared by 31.33% to $919.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $919.9 million, $946.6 million, and $888.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.